Tuis207940 • KRX
add
Samsung Biologics Co Ltd
Vorige sluiting
₩1 034 000,00
Dagwisseling
₩1 015 000,00 - ₩1 040 000,00
Jaarwisseling
₩722 000,00 - ₩1 209 000,00
Markkapitalisasie
72,53 bn KRW
Gemiddelde volume
80,03 k
P/V-verhouding
56,68
Dividend-opbrengs
-
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (KRW) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 1,30 bn | 37,11% |
Bedryfskoste | 241,41 mjd | 22,51% |
Netto inkomste | 375,55 mjd | 109,38% |
Netto winsgrens | 28,93 | 52,75% |
Wins per aandeel | 5,28 k | 109,40% |
EBITDA | 650,09 mjd | 78,25% |
Effektiewe belastingkoers | 24,80% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (KRW) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 1,29 bn | -37,61% |
Totale bates | 17,44 bn | 5,53% |
Totale aanspreeklikheid | 6,16 bn | -5,47% |
Totale ekwiteit | 11,28 bn | — |
Uitstaande aandele | 71,17 m | — |
Prys om te bespreek | 6,52 | — |
Opbrengs op bates | 7,00% | — |
Opbrengs op kapitaal | 9,70% | — |
Kontantvloei
Netto kontantverandering
| (KRW) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 375,55 mjd | 109,38% |
Kontant van bedrywe | 682,98 mjd | 135,64% |
Kontant van beleggings | -250,22 mjd | -142,78% |
Kontant van finansiering | -69,80 mjd | 65,49% |
Netto kontantverandering | 360,84 mjd | -47,87% |
Beskikbare kontantvloei | -103,14 mjd | -115,61% |
Meer oor
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.
The company has partnered with pharmaceutical companies such as Pfizer, GlaxoSmithKline, Eli Lilly, AstraZeneca and Bristol-Myers Squibb. Wikipedia
HUB
Gestig
2011
Webwerf
Werknemers
4 770
